Q3 EPS Forecast for Cognition Therapeutics Lifted by Analyst

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at Brookline Capital Management lifted their Q3 2025 earnings estimates for shares of Cognition Therapeutics in a research note issued to investors on Tuesday, September 2nd. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.09). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.34) EPS.

A number of other research firms have also recently commented on CGTX. Wall Street Zen upgraded shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Thursday, June 26th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $2.83.

Cognition Therapeutics Stock Up 0.8%

CGTX opened at $2.61 on Friday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The company has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $0.67. The stock has a market cap of $191.89 million, a P/E ratio of -3.90 and a beta of 1.33.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northeast Financial Consultants Inc boosted its stake in shares of Cognition Therapeutics by 158.6% during the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after buying an additional 38,851 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares during the last quarter. CM Management LLC boosted its stake in shares of Cognition Therapeutics by 100.0% during the 1st quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $168,000 after buying an additional 200,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Cognition Therapeutics by 814.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after buying an additional 897,353 shares during the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.